Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) and Lepu Biotechnology Co., Ltd (HKG: 2157) have announced significant progress in the co-development of their trispecific T cell connector, having identified a WT1/HLA-A02 targeted T-cell connector, WT1×CD3×4-1BB trispecific antibody, as part of their collaboration initiated last year.
Pre-clinical data for this product has demonstrated robust anti-tumor activities against both hematological malignancies and solid tumors, with results expected to be presented at the American Association for Cancer Research (AACR) annual meeting in the following year.
Wilms’ tumor gene 1 (WT1) is known for its high expression in various cancer tumor cells, with its peptide fragments presented on tumor cell surfaces via MHC molecules and nearly absent in normal tissues, making it an optimal target for cancer immunotherapy. Developing antibodies against MHC I complexes that target intracellular antigens has been a significant challenge. Biocytogen has leveraged its human antibody mouse RenMab to create RenTCR mimic mice, combining multiple immune methodologies and high-throughput screening platforms to establish a human TCR mimic (TCRm) antibody discovery platform. Using this platform, Biocytogen has successfully identified WT1 antibodies with improved specificity and higher affinity compared to control drugs.- Flcube.com
